Literature DB >> 34202849

Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.

Natalia Martinez-Acuña1,2, Diana Minerva Avalos-Nolazco1, Diana Raquel Rodriguez-Rodriguez1, Cynthia Gabriela Martinez-Liu1,2, Kame Alberto Galan-Huerta1,2, Gerardo Raymundo Padilla-Rivas1, Javier Ramos-Jimenez2,3, Sergio Ayala-de-la-Cruz4, Eduardo Cienfuegos-Pecina4, Erik Alejandro Diaz-Chuc4, Rogelio Cazares-Tamez4, Amador Flores-Arechiga4, Fernando Perez-Chavez4, Daniel Arellanos-Soto1,2, Sonia Amelia Lozano-Sepulveda1,2, Elvira Garza-Gonzalez1, Consuelo Treviño-Garza5,6, Roberto Montes-de-Oca-Luna6,7, Aurora Beatriz Lee-Gonzalez6,8, Manuel Enrique de-la-O-Cavazos5,6, Ana Maria Rivas-Estilla1,2.   

Abstract

The progression and distribution of the SARS-CoV-2 pandemic are continuously changing over time and can be traced by blood donors' serological survey. Here, we investigated the seroprevalence of anti-SARS-CoV-2 antibodies in blood donors in Nuevo Leon, Mexico during 2020 as a strategy for the rapid evaluation of the spread of SARS-CoV-2 and asymptomatic case detection. We collected residual plasma samples from blood donors who attended two regional donation centers from January to December of 2020 to identify changes in anti-SARS-CoV-2 IgG prevalence. Plasma samples were analyzed on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG chemiluminescent assay. We found a total of 99 reactive samples from 2068 analyzed plasma samples, resulting in a raw prevalence of 4.87%. Donors aged 18-49 years were more likely to be seropositive compared to those aged >50 years (p < 0.001). Weekly seroprevalence increased from 1.8% during the early pandemic stage to 27.59% by the end of the year. Prevalence was 1.46-fold higher in females compared to males. Case geographical mapping showed that Monterrey city recorded the majority of SARS-CoV-2 cases. These results show that there is a growing trend of seroprevalence over time associated with asymptomatic infection that is unnoticed under the current epidemiological surveillance protocols.

Entities:  

Keywords:  COVID-19; Mexico; anti-SARS-CoV-2 IgG; blood donors; seroprevalence

Mesh:

Substances:

Year:  2021        PMID: 34202849     DOI: 10.3390/v13071225

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  24 in total

1.  Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism.

Authors:  Sarthak Gupta; Shuichiro Nakabo; Luz P Blanco; Liam J O'Neil; Gustaf Wigerblad; Rishi R Goel; Pragnesh Mistry; Kan Jiang; Carmelo Carmona-Rivera; Diana W Chan; Xinghao Wang; Hege L Pedersen; Manasi Gadkari; Katherine N Howe; Faiza Naz; Stefania Dell'Orso; Sarfaraz A Hasni; Caeden Dempsey; Ashley Buscetta; Pamela A Frischmeyer-Guerrerio; Paul Kruszka; Maximilian Muenke; Luis M Franco; Hong-Wei Sun; Mariana J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

2.  Constant risk of dengue virus infection by blood transfusion in an endemic area in Mexico.

Authors:  D Arellanos-Soto; V B-d l Cruz; N Mendoza-Tavera; J Ramos-Jiménez; R Cázares-Taméz; A Ortega-Soto; A M Rivas-Estilla
Journal:  Transfus Med       Date:  2015-04-16       Impact factor: 2.019

Review 3.  SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Shafiul Haque; Ranjit Sah; Ruchi Tiwari; Yashpal Singh Malik; Kuldeep Dhama; M Iqbal Yatoo; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales
Journal:  Infez Med       Date:  2020 Ahead Of Print Jun 1

4.  Covid-19: Nine in 10 pregnant women with infection when admitted for delivery are asymptomatic, small study finds.

Authors:  Susan Mayor
Journal:  BMJ       Date:  2020-04-14

5.  Antibody responses to SARS-CoV-2 in patients with COVID-19.

Authors:  Quan-Xin Long; Bai-Zhong Liu; Hai-Jun Deng; Gui-Cheng Wu; Kun Deng; Yao-Kai Chen; Pu Liao; Jing-Fu Qiu; Yong Lin; Xue-Fei Cai; De-Qiang Wang; Yuan Hu; Ji-Hua Ren; Ni Tang; Yin-Yin Xu; Li-Hua Yu; Zhan Mo; Fang Gong; Xiao-Li Zhang; Wen-Guang Tian; Li Hu; Xian-Xiang Zhang; Jiang-Lin Xiang; Hong-Xin Du; Hua-Wen Liu; Chun-Hui Lang; Xiao-He Luo; Shao-Bo Wu; Xiao-Ping Cui; Zheng Zhou; Man-Man Zhu; Jing Wang; Cheng-Jun Xue; Xiao-Feng Li; Li Wang; Zhi-Jie Li; Kun Wang; Chang-Chun Niu; Qing-Jun Yang; Xiao-Jun Tang; Yong Zhang; Xia-Mao Liu; Jin-Jing Li; De-Chun Zhang; Fan Zhang; Ping Liu; Jun Yuan; Qin Li; Jie-Li Hu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-04-29       Impact factor: 53.440

6.  [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].

Authors: 
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2020-02-10

7.  The prevalence of antibodies to SARS-CoV-2 among blood donors in China.

Authors:  Le Chang; Wangheng Hou; Lei Zhao; Yali Zhang; Yanbin Wang; Linfeng Wu; Tingting Xu; Lilin Wang; Juan Wang; Jian Ma; Lan Wang; Junpeng Zhao; Jing Xu; Juan Dong; Ying Yan; Ru Yang; Yu Li; Fei Guo; Wenjuan Cheng; Yingying Su; Jinfeng Zeng; Wei Han; Tong Cheng; Jun Zhang; Quan Yuan; Ningshao Xia; Lunan Wang
Journal:  Nat Commun       Date:  2021-03-02       Impact factor: 14.919

8.  SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.

Authors:  Dianna L Ng; Gregory M Goldgof; Brian R Shy; Andrew G Levine; Joanna Balcerek; Sagar P Bapat; John Prostko; Mary Rodgers; Kelly Coller; Sandra Pearce; Sergej Franz; Li Du; Mars Stone; Satish K Pillai; Alicia Sotomayor-Gonzalez; Venice Servellita; Claudia Sanchez San Martin; Andrea Granados; Dustin R Glasner; Lucy M Han; Kent Truong; Naomi Akagi; David N Nguyen; Neil M Neumann; Daniel Qazi; Elaine Hsu; Wei Gu; Yale A Santos; Brian Custer; Valerie Green; Phillip Williamson; Nancy K Hills; Chuanyi M Lu; Jeffrey D Whitman; Susan L Stramer; Candace Wang; Kevin Reyes; Jill M C Hakim; Kirk Sujishi; Fariba Alazzeh; Lori Pham; Edward Thornborrow; Ching-Ying Oon; Steve Miller; Theodore Kurtz; Graham Simmons; John Hackett; Michael P Busch; Charles Y Chiu
Journal:  Nat Commun       Date:  2020-09-17       Impact factor: 14.919

9.  Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea.

Authors:  Seungjae Lee; Tark Kim; Eunjung Lee; Cheolgu Lee; Hojung Kim; Heejeong Rhee; Se Yoon Park; Hyo-Ju Son; Shinae Yu; Jung Wan Park; Eun Ju Choo; Suyeon Park; Mark Loeb; Tae Hyong Kim
Journal:  JAMA Intern Med       Date:  2020-11-01       Impact factor: 21.873

10.  Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.

Authors:  Craig P Thompson; Nicholas E Grayson; Robert S Paton; Jai S Bolton; José Lourenço; Bridget S Penman; Lian N Lee; Valerie Odon; Juthathip Mongkolsapaya; Senthil Chinnakannan; Wanwisa Dejnirattisai; Matthew Edmans; Alex Fyfe; Carol Imlach; Kreepa Kooblall; Nicholas Lim; Chang Liu; César López-Camacho; Carol McInally; Anna L McNaughton; Narayan Ramamurthy; Jeremy Ratcliff; Piyada Supasa; Oliver Sampson; Beibei Wang; Alexander J Mentzer; Marc Turner; Malcolm G Semple; Kenneth Baillie; Heli Harvala; Gavin R Screaton; Nigel Temperton; Paul Klenerman; Lisa M Jarvis; Sunetra Gupta; Peter Simmonds
Journal:  Euro Surveill       Date:  2020-10
View more
  2 in total

1.  Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.

Authors:  Miguel A Fernández-Rojas; Marco A Luna-Ruiz Esparza; Abraham Campos-Romero; Diana Y Calva-Espinosa; José L Moreno-Camacho; Fela Mendlovic; Tanya Plett-Torres; Jonathan Alcántar-Fernández
Journal:  Sci Rep       Date:  2022-03-28       Impact factor: 4.379

2.  Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico.

Authors:  Victor Monteón; Floribeth Leon Pérez; Virginia Peña Hernández; Anatalia Osorio Pacheco; Pedro Fuentes Guzman; Gicel Ivett Gutiérrez Torres
Journal:  Transfus Apher Sci       Date:  2022-01-31       Impact factor: 2.596

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.